Matthew Harrison analyst MORGAN STANLEY

Currently, out of the existing stock ratings of Matthew Harrison - 392 which are a Hold (41.66%), 471 which are a Buy (50.05%), 78 which are a Sell (8.29%)

Matthew Harrison

Work Performance Price Targets & Ratings Chart

Analyst Matthew Harrison works at MORGAN STANLEY and is covering Healthcare, Technology, Basic Materials, Energy sectors with 2,131 price targets and ratings displayed on 85 stocks.

Matthew Harrison's average stock forecast success ratio is 60.59% with an average time for price targets to be met of 186.25 days.

Most recent stock forecast was given on VACC, at 25-Sep-2023.

Wall Street Analyst Matthew Harrison

Analyst best performing recommendations are on CMRX (CHIMERIX).
The best stock recommendation documented was for CMRX (CHIMERIX) at 2/23/2016. The price target of $5 was fulfilled within 1 day with a profit of $0.54 (12.11%) receiving and performance score of 121.08.

Average potential price target upside

ADCT ADGI ALVR ALXN AMGN Amgen ARGX argenx SE AVIR Atea Pharmaceuticals BGNE BeiGene, Ltd BHVN Biohaven Pharmaceutical Holding Company Ltd BIIB Biogen BLUE bluebird bio BMRN BioMarin Pharmaceutical BMY BristolMyers Squibb Company BNTX BioNTech SE Sponsored ADR CCMP Cabot Microelectronics CELG DNLI Denali Therapeutics EVLO Evelo Biosciences FULC FUSN GBT Global Blood Therapeutics GLPG Galapagos NV HUN Huntsman IMGN ImmunoGen INSM Insmed KLDO Kaleido BioSciences KOD Kodiak Sciences LEGN MRK Merck . MRNA Moderna PFE Pfizer PTLA REGN Regeneron Pharmaceuticals RPM RPM International SGEN Seattle Genetics SGTX Sigilon Therapeutics SRPT Sarepta Therapeutics VRTX Vertex Pharmaceuticals VVV Valvoline ABBV AbbVie GILD Gilead Sciences JNJ Johnson & Johnson RDUS Radius Health SAGE Sage Therapeutics ALNY Alnylam Pharmaceuticals CERE Cerevel Therapeutics Holdings CNTA EDIT Editas Medicine FUL H.B. Fuller Company GMAB Genmab A/S IMMU IMRA IMARA LLY Eli Lilly and Company RGNX REGENXBIO TSVT ADAG AKRO Akero Therapeutics BOLT PHVS VACC XLRN Acceleron Pharma ALEC CABA CYTK Cytokinetics INCY yte RUBY ZNTL Zentalis Pharmaceuticals SANA TNYA APD Air Products and Chemicals AXTA Axalta Coating Systems Ltd CMRX Chimerix ENTG Entegris FTSV GRA INVA IOBT IVVD KOP Koppers Holdings KWR Quaker Chemical LYEL MTX SHW The SherwinWilliams Company UBX Unity Biotechnology VIGL

Analyst name


Current price target

Potential distance

Previous price target


Price targets met ratio

Average potential upside

Average time for PT to be met

Performance score



$11.12 (1263.64%)


9 days ago

0/6 (0%)

$17.51 (547.56%)



$7.12 (809.09%)


16 days ago

0/8 (0%)

$10.38 (287.95%)



$4.12 (468.18%)


8 months 4 days ago

1/9 (11.11%)

$12.1 (74.04%)




$6.12 (695.45%)


10 months 19 days ago

0/2 (0%)

$9.09 (69.18%)



$2.7 (117.39%)


1 years 7 days ago

1/2 (50%)

$11.44 (49.05%)


Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Matthew Harrison is most bullish on?

Potential upside of $126.82 has been obtained for BGNE (BEIGENE, LTD)

Which stock is Matthew Harrison is most reserved on?

Potential downside of -$2.55 has been obtained for GMAB (GENMAB A/S)

What Year was the first public recommendation made by Matthew Harrison?

On 2012

To continue looking at which analysts cover the stock please register to the basic or advanced membership

How to use the chart